ICON plc (ICLR)
NASDAQ: ICLRHealth CareBiotechnology: Commercial Physical & Biological ResarchUSD
Market open · Delayed 15 min · as of Oct 8, 3:23 PM ET
ICLR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $12.63B
- P/E (TTM)
- 172.29
- Forward P/E
- 13.85
- EPS (TTM)
- $0.95
- Dividend yield
- None
- 52-week range
- 66.57 – 203.91
- Day range
- 159.40 – 164.35
- Volume / Avg
- 633.07K / 814.74K
- Beta
- —
- Shares outstanding
- 77.15M
- Next earnings
- Oct 28, 2026
52-week range
ICLR stock today
On Oct 8, ICLR is trading at $163.68, shedding $0.405 (0.25%), versus the S&P 500's 0.52% decline. At this level, ICLR sits in the middle of its 52-week range of $66.57 to $203.91: 19.7% below the high, set on Jan 7, 2026 and 145.9% above the low. ICLR is down 10.0% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has lost 12.1%.
At 172.3x trailing earnings, ICON trades above the peer-group median of 35.2x. Its forward P/E of 13.8x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year. The company is scheduled to report Sep/2026 results on Oct 28; analysts expect EPS of $2.44.
Summary generated from market data by MetaCap's automated system. Methodology
About ICON
Company profileICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, contract staffing, data solutions, and laboratory services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization.
- Sector
- Health Care
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- CEO
- Mr. Barry Balfe
- Headquarters
- Dublin
- Employees
- 40,200
- IPO year
- 1998
- Website
- iconplc.com
Financial highlights
Full financialsIn fiscal 2025, ICON generated $8.25 billion in revenue, up 0.8% from fiscal 2024, its 5th consecutive year of revenue growth. Net income was $229.3 million (-69.0% year over year), for a net margin of 2.8% versus a median of 6.9% in the prior 5 years. Gross margin was 26.4% (down from 28.6%) and operating margin 5.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $8.25B | $8.19B | $8.05B | $7.74B | $5.48B |
| Growth | +0.76% | +1.66% | +4.05% | +41.24% | +95.93% |
| Net income | $229.34M | $739.13M | $554.21M | $505.30M | $153.19M |
| EPS (diluted) | $2.90 | $8.90 | $6.70 | $6.13 | $2.25 |
Analyst forecast
ForecastConsensus (18 analysts)
buy
Avg. price target
$184.41+12.67%
- Strong buy 1
- Buy 9
- Hold 7
- Sell 0
- Strong sell 1
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Oct 28, 2026
- EPS estimate
- $2.44
ICLR news
All ICLR newsICON peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CRLCharles River Laboratories International Inc. | 293.65 | -2.22% | $14.14B | vs ICLR |
| MEDPMedpace Holdings Inc. | 598.86 | -0.89% | $16.72B | vs ICLR |
| INCYIncyte Corp. | 113.13 | -0.28% | $22.93B | vs ICLR |
| ABSIAbsci Corporation | 8.95 | -2.93% | $1.54B | vs ICLR |
| OABIOmniAb Inc. | 4.59 | +0.55% | $666.61M | vs ICLR |
| NRCNRC Health | 20.36 | +0.84% | $450.35M | vs ICLR |
| MXCTMaxCyte Inc. | 0.9933 | -4.49% | $102.51M | vs ICLR |
| ONMDOneMedNet Corp Class A | 4.75 | -3.26% | $27.67M | vs ICLR |
Indexes, lists and sector
ICON stock FAQ
What is ICON's stock price today?
ICLR last traded at $163.68 as of Oct 8, 3:23 PM EDT, down 0.25% on the day. Prices are delayed at least 15 minutes.
Does ICON pay a dividend?
No. ICON does not currently pay a regular cash dividend.
When is ICON's next earnings date?
ICON is expected to report earnings on Wednesday, October 28, 2026. Analysts expect EPS of $2.44.
What is ICLR's P/E ratio?
ICLR trades at a trailing P/E ratio of 172.29 and a forward P/E of 13.85, compared with a median of 35.2 for its closest peers.
Who is ICON's CEO?
Mr. Barry Balfe is the chief executive officer of ICON plc, which has about 40,200 employees.
Has ICLR ever split its stock?
Yes. The most recent ICLR stock split was a 2-for-1 split on Aug 13, 2008, one of 2 splits on record.
What is the ICLR 52-week high?
The 52-week high for ICLR is $203.91 and the 52-week low is $66.57. The stock is currently 19.7% below its high.